Get the Weekly Intelligence Brief — top committee picks every Sunday.
RGEN · NASDAQ · STOCK

Repligen (RGEN) Stock Analysis

Healthcare Updated August 17, 2026
$169.06
52W $100.99 – $175.77
61/100
$9.42B
225.4
1.01
AI Committee Verdict
Buy
61/100
Conviction: Contested · 50% agreement · 6 analysts
+1.7%
-2.6%
0.63:1
Contested
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.

Is RGEN Bullish or Bearish?

Bullish. Innellis AI committee rates Repligen (RGEN) Buy with a composite score of 61/100 , based on 6 analysts with 50% agreement. Last updated August 17, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +14.47 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -5.53 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 227.0 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Low leverage (debt-to-equity 0.26) -- balance sheet can absorb a shock — Risk
Bear Case
  • P/E of 227.0 is expensive by classic value standards — Value
  • Price-to-book of 4.4x prices in significant intangible value — Value
  • ROE of only 2.0% -- cheap may mean cheap for a reason — Value
  • RSI at 77 is in overbought territory — Technical
  • Bollinger bandwidth of 33.2% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 17, 2026
Overall Committee Score
61/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 42%
of 192 Healthcare peers
Value Analyst bearish
38 / 100 · High confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 227.0 is expensive by classic value standards
Growth Analyst bullish
77 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ 4 consecutive earnings beats -- consistent execution
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 77 is in overbought territory
Risk Analyst neutral
58 / 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.26) -- balance sheet can absorb a shock
− Bollinger bandwidth of 33.2% signals elevated volatility
Macro Analyst bullish
80 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst neutral
53 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2963.04)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 60.5 to 60.5.

Analyst-level changes:
  • Portfolio Manager: +1 bearish signal(s).

Comparing 2026-08-16 to 2026-08-17 (1 day apart).

Technical Analysis

RSI (14)
77.1
Overbought
MACD Histogram
1.756
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$162.47
Resistance
$169.64
Bollinger %B
0.84
Inside Bands
Price vs Moving Averages
EMA 9
$161.47 Above
EMA 21
$153.68 Above
EMA 50
$143.99 Above
EMA 200
$136.94 Above

Fundamental Analysis

Valuation
52
Growth
94
Profitability
33
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio 225.4×
P/B Ratio 4.45×
PEG Ratio 0.27
Dividend Yield 0.00%
52W High $175.77
52W Low $100.99
Quality & Growth
ROE 232.1%
ROA 165.8%
Gross Margin 5105.1%
Operating Margin 831.7%
Revenue Growth YoY
Debt / Equity 0.33
AI Fundamental Assessment
P/E ratio of 225.4 (rich relative to a 15-40x range); Price-to-book of 4.5x; PEG ratio of 0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 2.3%; Return on assets of 1.7%; Net margin of 5.3%; Gross margin of 51.1%; Current ratio of 9.05 (healthy short-term liquidity); Debt-to-equity of 0.33; Free cash flow per share is positive (1.96); Most recent quarter beat estimates by 18.0%; 4 consecutive earnings beats; EPS growth accelerating (-2.0% -> +12.5% QoQ); Average YoY EPS growth of 46.0%; Analyst estimates rising over recent quarters
Get the Full RGEN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore RGEN Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime